Aldeyra Therapeutics (ALDX) vs Apollomics (APLM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apollomics (APLM) has outperformed Aldeyra Therapeutics (ALDX) over the past year, gaining 18.2% versus a loss of 83.1%. Apollomics is the larger company by market cap ($62.4 million vs $56.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALDX | APLM |
|---|---|---|
| Share price | $0.9302 | $21.42 |
| Market cap | $56.12M | $62.44M |
| 1-day change | -1.85% | -1.29% |
| YTD return | -81.70% | +16.50% |
| 1-year return | -83.14% | +18.16% |
| 5-year return | -88.64% | — |
| EPS (TTM) | $-0.38 | $-7.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.93 | $42.12 |
| 52-week low | $0.862 | $10.01 |
| Distance from 52-week high | -84.31% | -49.15% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +609.52% | — |
| Average volume | 1.18M | 21.69K |
| Shares outstanding | 60.33M | 2.91M |
| Employees | 6 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- APLM has outperformed ALDX by 101.3 percentage points over the past year.
About Aldeyra Therapeutics
ALDX stock →Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
ALDX vs APLM FAQ
Which is bigger, Aldeyra Therapeutics or Apollomics?
Apollomics (APLM) is larger, with a market capitalization of $62.44M compared with $56.12M for Aldeyra Therapeutics (ALDX).
Which stock has performed better over the past year, ALDX or APLM?
APLM returned +18.16% over the past 12 months, compared with -83.14% for ALDX (price return, excluding dividends). Past performance does not predict future results.
Are Aldeyra Therapeutics and Apollomics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.